BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance

  For Q3 2017, Total revenues were $149.4 million, an increase of 5% as compared to 2016.

  November 3, 2017

   · 

  23 min read
• Business

  Pacific Biosciences Appoints Kathy Ordonez as Chief Commercial Officer

  Ms. Ordonez brings more than thirty years of experience in the life sciences and diagnostics industries, with senior roles at Hoffmann-La Roche, Celera, Quest Diagnostics and RainDance Technologies.

  November 3, 2017

   · 

  3 min read
• Business

  Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update

  At September 30, 2017, Corvus had cash, cash equivalents and marketable securities totaling $99.7 million compared to cash, cash equivalents and marketable securities of $134.9 million at December 31, 2016.

  November 3, 2017

   · 

  7 min read
• Business

  Obalon Therapeutics and Sono Bello Announce Agreement to Offer Novel Weight Loss Treatment in Sono Bello Centers

  The Obalon Balloon System will be the exclusive non-invasive weight loss technology offered in Sono Bello centers.

  November 3, 2017

   · 

  4 min read
• Business

  Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results

  Cash, cash equivalents and marketable securities totaled $259.4 million at September 30, 2017, compared with $197.3 million at December 31, 2016.

  November 3, 2017

   · 

  9 min read
• Business

  Fluidigm Announces Third Quarter Financial Results and Operational Progress

  Total revenue for the third quarter was $24.7 million, an increase of 12% from $22.2 million in the third quarter of 2016 and an increase of 3% from $23.9 million in the second quarter of 2017.

  November 3, 2017

   · 

  18 min read
• Business

  Corcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update

  Third quarter revenue of $42.8 million, an increase of 97 percent from third quarter 2016.

  November 3, 2017

   · 

  10 min read
• Business

  OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights

  As of September 30, 2017, cash, cash equivalents and short-term investments totaled $113.6 million.

  November 3, 2017

   · 

  10 min read
• Business

  T2 Biosystems Reports Third Quarter 2017 Financial Results and Provides Company Update

  Reported third quarter total revenue of $1.1 million, in line with guidance. Product revenue of $739,000, was a $159,000 or 27.4% increase from the third quarter of 2016.

  November 3, 2017

   · 

  11 min read
• Business

  Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate Update

  For the third quarter of 2017, Ultragenyx reported a net loss of $79.2 million, or $1.87 per share.

  November 3, 2017

   · 

  11 min read